ISRCTN11916376 https://doi.org/10.1186/ISRCTN11916376

International Collaborative Ovarian Neoplasm studies (1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Submission date 06/04/2000	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 06/04/2000	**Overall study status** Completed	
Last Edited 31/12/2021	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Sarah Wheeler

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
-
abc@email.com

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00002477

Protocol serial number
ICON1

Study information

Scientific Title
International Collaborative Ovarian Neoplasm studies 1 (ICON1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Acronym
ICON1

Study objectives
Currently it is not known whether adjuvant chemotherapy is of any benefit in ovarian cancer, and all previous trials have been too small to give reliable evidence. The prognosis for early disease is much better than for advanced disease, which is known to respond to platinum-based chemotherapy, and a similar response in early disease would prolong the lives of many thousands of women each year. However, any benefit must be weighed against the toxicity associated with the treatment employed, and hence reliable evidence regarding the size of any benefit to adjuvant treatment is needed.

The aim of the study was to compare immediate with deferred chemotherapy in patients with early stage epithelial ovarian cancer

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Cancer

Interventions
Immediate chemotherapy or chemotherapy deferred until indicated

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Survival time; recurrence-free survival.

Key secondary outcome(s))

Not provided at time of registration

Completion date
21/01/2000

Eligibility

Key inclusion criteria
1. Chemotherapy not clearly indicated
2. No previous malignancy
3. No prior radiotherapy or chemotherapy
4. No contraindication to chemotherapy

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Female

Total final enrolment
477

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1991

Date of final enrolment
21/01/2000

Locations

Countries of recruitment
United Kingdom

England

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	Long-term follow-up	20/06/2007	31/12/2021	No	No

Other publications	01/11/2001	Yes	No
Other publications	15/01/2003	Yes	No
Other publications	01/11/2003	Yes	No
Other publications	01/11/2003	Yes	No